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Background: Oesophageal adenocarcinoma (OAC) is one of the fastest rising malignancies with continued poor prognosis.
Many studies have proposed novel biomarkers but, to date, no immunohistochemical markers of survival after oesophageal
resection have entered clinical practice. Here, we systematically review and meta-analyse the published literature, to identify
potential biomarkers.
Methods: Relevant articles were identified via Ovid medline 1946–2013. For inclusion, studies had to conform to REporting
recommendations for tumor MARKer (REMARK) prognostic study criteria. The primary end-point was a pooled hazard ratio (HR)
and variance, summarising the effect of marker expression on prognosis.
Results: A total of 3059 articles were identified. After exclusion of irrelevant titles and abstracts, 214 articles were reviewed in full.
Nine molecules had been examined in more than one study (CD3, CD8, COX-2, EGFR, HER2, Ki67, LgR5, p53 and VEGF) and were
meta-analysed. Markers with largest survival effects were COX-2 (HR¼ 2.47, confidence interval (CI)¼ 1.15–3.79), CD3 (HR¼ 0.51,
95% CI¼ 0.32–0.70), CD8 (HR¼ 0.55, CI¼ 0.31–0.80) and EGFR (HR¼ 1.65, 95% CI¼ 1.14–2.16).
Discussion: Current methods have not delivered clinically useful molecular prognostic biomarkers in OAC. We have highlighted
the paucity of good-quality robust studies in this field. A genome-to-protein approach would be better suited for the
development and subsequent validation of biomarkers. Large collaborative projects with standardised methodology will be
required to generate clinically useful biomarkers.
Oesophageal adenocarcinoma (OAC) is one of the fastest rising
cancers in men in the UK and now accounts for more than 5700
new cases per year (Rouvelas et al, 2005; National Oesophago-
Gastric Cancer audit, 2013; Peng et al, 2013). There is an urgent
need to identify prognostic subtypes of OAC as despite potentially
curative treatment, 5-year survival is only 35–40% and current
pathological prognostic markers are unreliable. The systematic
identification of molecular prognostic markers would allow for
improved prognostic information for the patient and a better
understanding of the underlying tumour biology. This will help in
the logical development of novel targeted therapies for these
patients.
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OAC is an area of unmet research need and has been
highlighted as a research priority by governments and in the
strategies of large funding bodies (Chen et al, 2012). Predicting
prognosis after potentially curative surgery for OAC is difficult and
inaccurate. It is currently based on internationally accepted tumour
staging (Tumour Node Metastasis), with the addition of other
important pathological criteria including resection margin status,
the presence of vascular or neural invasion and of signet ring
histology (Sobin et al, 2010; O’Neill et al, 2013; Schoppmann et al,
2013b; Yendamuri et al, 2013). It is now well recognised that in
addition to pathological scoring systems other features of tumours,
for example, constituents of the microenvironment, immune
infiltration and response to neoadjuvant chemotherapy (NAC),
are critical to tumour progression (Courrech Staal et al, 2011).
A good response to NAC has been consistently shown to predict
for better outcome (Mandard et al, 1994; Fareed et al, 2009; Noble
et al, 2013). This is being used by some clinicians to determine
adjuvant treatment protocols, but this can only be accurately
determined after oesophageal resection, and even in those patients
where a poor local tumour response to NAC is observed, a
proportion may benefit from systemic treatment by virtue of nodal
downstaging (Noble et al, 2013).
Recent advances in OAC have focused on early diagnosis and
understanding the genetic landscape of the disease (Kadri et al,
2010; Liu et al, 2014). Next-generation sequencing studies may
ultimately lead to molecular phenotype therapeutics in OAC but
the widespread application of near-patient whole-genome sequen-
cing at the time of diagnosis is likely to be many years away (Dulak
et al, 2013; Weaver et al, 2014). Immunohistochemical (IHC)
analysis of differentially expressed proteins is currently superior to
DNA-based biomarkers in terms of availability, labour require-
ments, determining cellular localisation of a marker and takes into
consideration post-transcriptional processing. IHC is routinely
used in pathology laboratories to differentiate between subtypes of
oesophageal cancer and guides targeted therapy with biological
agents in a range of cancer types (DiMaio et al, 2012; Ward et al,
2013). A number of IHC-based prognostic biomarkers have been
reported in OAC, but none have entered clinical practice
(Waterman et al, 2004; Ong et al, 2013).
In this systematic review and meta-analysis, we sought to
carefully assess the available published literature on prognostic
IHC biomarkers of survival in the resected tumour from patients
with OAC. The objective of the study was to identify prognostic
markers to provide improved risk stratification in addition to
highlighting molecular targets that could offer strategies for the
development of novel therapies for patients with OAC.
MATERIALS AND METHODS
Identification of literature. The aim of the search was to identify
all primary literature examining IHC markers of prognosis in
OAC. A search strategy combining Plain Text and Medical Subject
Heading terms was developed:
(1) (esoph* OR oeoph*) AND (carcinoma OR adenocarcinoma
OR cance* OR neoplas* OR tumo*) AND (Prognos* OR Surviv*
OR Mortal*) AND (protei* OR marke* OR biomark*)
OR
(2) Oesophageal Neoplasms/AND (prognosis/or disease-free
survival (DFS)/OR Survival/OR mortality/or ‘cause of death’/or
fatal outcome/or survival rate/) AND (biological markers/or exp
antigens, differentiation/or genetic markers/or exp tumour mar-
kers, biological/OR genes/or exp genes, neoplasm/) AND Adeno-
carcinoma/.
The search term was entered into Ovid MEDLINE (1946 to
November 2013) without limits and 3059 articles were returned
(Figure 1). Existing systematic reviews and reference lists were
crosschecked for studies missed by the search term. In cases where
studies were derived from the same data set, the more recent or
most complete article was retained. Only published results are
included in this review. The Preferred Reporting Items for
Systematic Review and Meta-Analysis were utilised (Moher et al,
2009).
Screening. Two independent reviewers (FN and LMM) examined
3059 study titles. From these study titles, 695 abstracts were
brought forward as relevant to this study. On review of the
abstracts, potentially eligible full-text articles were retrieved with
relevant appendices and Supplementary Information.
Eligibility and data extraction. Full-text articles were reviewed
against quality criteria (Table 1) derived from the REporting
recommendations for tumour MARKer prognostic studies criteria
(REMARK – published guidelines for quality reporting in IHC-
based tumour biomarker studies; McShane et al, 2005).
For relevant articles, variables were extracted. These included
the following: first name author, IHC target, year of publication,
number of cases, primary antibody used, dilution of primary
antibody, reference group for statistical analysis, number of
positive stained cases, univariate or multivariate analysis, hazard
ratio (HR), 95% confidence interval (CI), P-value, location of stain
and type of survival (overall survival (OS), cancer-specific survival
(CSS) or DFS. Only CSS and OS were pooled in the meta-analysis).
Records identified through OVID,
n = 3059.
Irrelevant titles excluded,
n = 2364
Irrelevant abstracts excluded,
n = 482
Abstracts screened for relevance,
n = 695
Full text assessed for eligibility,
n = 214
Studies included systematic review,
n = 36
Identification
Screening
Eligibility
Included
Additional articles identified via
expertise, n = 1. Review of other
meta-analysis, n = 0.
Excluded full text, n = 178.
No HR: 55. SCC+ OAC combined:43.
SCC:25.Non-IHC: 23. No survival: 14.
Inadequate cohort description: 7.
Gastric: 6. Repeated cohort: 4.
Figure 1. PRISMA flow chart illustrating stages of selection of final
articles for meta-analysis.
Table 1. Inclusion criteria adapted from REMARK criteria,
utilised at eligibility stage of selection
1 Prospective or retrospective cohort design with a well-defined study
population with justification for excluded cases
2 Assay of primary/neoadjuvant resected OAC tumour specimens
3 Clear description of methods for tissue handling and IHC, including
antigen retrieval, selection, and preparation of both primary and
secondary antibodies, as well as visualisation techniques
4 A clear statement on the choice of positive and negative controls and
on the outcome of the assay to ensure that the primary antibody used
was a well-validated reagent
5 Statistical analysis using univariate or multivariate hazards modelling
6 Reporting of the resulting HRs including 95% CIs and P-values
Abbreviations: CI¼ confidence interval; IHC¼ immunohistochemical; HR¼ hazard ratio;
OAC¼oesophageal adenocarcinoma; REMARK¼REporting recommendations for tumor
MARKer.
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Synthesis and statistical analysis. Both univariate and multi-
variate results were considered for the meta-analysis, with
univariate analysis used preferentially when both were available.
Univariate analysis was preferred due to the variability of analysis
used (univariate n¼ 3; multivariate n¼ 5; and both n¼ 27). In
addition, there was variability in the method and variables used to
derive the final multivariate model making comparative analysis
across studies biased (Supplementary Figure 1). Of 36 studies
included in the review, 27 (75%) stated HR and CI derived by
multivariate analysis. Of these, the method used to make the model
was described in only nine (33%). The method used to make the
model varied as follows: entering all variables on univariate
analysis into the model in 6 (22%); using backward stepwise
regression in 2 (7%) and it was impossible to accurately assess the
method used in 19 (70%). The number of variables used to create
the multivariate model varied and was anywhere between 3 and 13.
Where studies considered opposite degrees of expression, the
inverse HR and CI was calculated to give results for high
expression. For biomarkers analysed in more than one study, HR
and CIs were entered into a random-effects model on Stata
Statistical Software, SE 12 (StataCorp LP, College Station, TX,
USA). The synthesised HR is reported as increase of risk of death
from OAC within the individual study’s reference group with
HR41 indicating increased risk of death, and HRo1 indicating
decreased risk of death.
The heterogeneity of results between studies was assessed using
I2 statistics (a measure of consistency of results between studies)
with increasing heterogeneity implying less utility in generalising
across studies (Higgins et al, 2003). Sensitivity analysis was carried
out by removing individual studies from the meta-analysis and
assessing the effect on the pooled result. Presence of publication
bias was formally evaluated using funnel plots (Figure 2) (Sterne
et al, 2001).
RESULTS
Excluded studies. Of the 3059 articles returned, 2364 were
excluded on review of title and 482 on examination of abstract,
leaving 214 articles considered relevant. Crosschecking of existing
systematic review reference lists revealed no further relevant
articles (Vallbohmer and Lenz, 2006; Ong et al, 2010; Chan et al,
2012; Chen et al, 2012, 2013; Peng et al, 2013; Gowryshankar
et al, 2014).
Upon careful review of the 214 articles against the REMARK
inclusion criteria, 56 did not provide a HR, 43 combined OAC and
SCC subtypes for statistical analysis, 25 examined only SCC, 23
used non-IHC methodology, 14 did not examine survival, 7 had
inadequate cohort description, 6 examined gastric cancer and 4
repeated use of a cohort. This left only 36 articles that conformed
to REMARK inclusion criteria.
Included studies. 26 individual research centres contributed to the
36 articles. 20 studies (56%) reported cohorts of patients who
underwent surgery only; in 6 studies (17%) the authors reported that
some patients had undergone neoadjuvant therapy and in 10 studies
(28%) no information were given regarding preoperative treatment.
Of the six studies, where some kind of neoadjuvant treatment was
reported, this consisted of chemoradiotherapy in five (14%) and
chemotherapy in three (8%). The percentage of patients who had
undergone neoadjuvant therapy varied from 8 to 100%. The specific
neoadjuvant treatment regimes that were used were only reported in
three out of six (50%) studies. Little overlap in methodology was seen
with every centre using different antibodies at different dilutions or
different scoring systems. Variable cohort sizes were used, ranging
from 24 to 259 cases. 50 HRs, CIs and relevant variables were
extracted from these studies. Extracted data is reported in Table 2
with biomarkers grouped according to the hallmark of cancer with
which a functional role for that molecule has been most closely
attributed (Figure 3; Hanahan and Weinberg, 2011).
19 of the 36 articles examined one or more of the same nine
molecules, making them suitable for meta-analysis. Upon pooling
studies, six of the nine molecules showed prognostic significance:
COX-2, CD3, CD8, p53, EGFR and HER2 in order of HR, with
LgR5, VEGF and Ki67 not reaching significance. Forrest plots are
shown in Figure 4.
In three of the studies included in the meta-analyses, only
multivariate analysis was stated. Where sensitivity analysis was not
possible due to lack of appropriate, robust literature, agreement on
prognostic value was considered with other studies on OAC.
COX-2. COX-2 is a rate-limiting enzyme in the conversion of
arachidonic acid to prostaglandins and has multiple functions in
immune evasion, angiogenesis and proliferation. COX-2 is
consistently detected with varying expression in OAC (Lagorce
et al, 2003). Subsequently, inhibitors of COX-2 have been shown to
be protective of progression from Barrett’s oesophagus to OAC,
and have shown some promise in improving prognosis when used
alongside NAC (Corley et al, 2003; Tuynman et al, 2005).
Three studies, consisting of a total of 382 patients, contributed
to quantify the effect of COX-2, which was found to correlate
negatively with prognosis (Buskens et al, 2002; Bhandari et al,
2006; Prins et al, 2012). Although consistent overexpression is
noted in OAC, differences in cutoff values for staining positivity,
and variability in numbers of positive staining cases between
studies are seen here (27% and 79% positive) (Buskens et al, 2002;
Prins et al, 2012). Within other prognostic studies on OAC, not
providing HR, both significant (three studies, n¼ 194) and non-
significant (three studies, n¼ 139) results have been reported
(Lagorce et al, 2003; France et al, 2004; Kulke et al, 2004; Heeren
et al, 2005; Mobius et al, 2005; Tuynman et al, 2008).
CD3. CD3þ cells are mature T lymphocytes and quantification
of CD3þ has been commonly used to evaluate immunological
response against solid tumours (Dahlin et al, 2011). Two studies
identified CD3 as an independent predictor of improved survival
in OAC (Rauser et al, 2010; Zingg et al, 2010). Methods of
exploration varied; with one study using an automated scoring
system across 10 random high-power fields vs central CD3þ
lymphocyte count (Rauser et al, 2010; Zingg et al, 2010). However,
the studies show good agreement (I2¼ 0.00%) and similar
weighting on meta-analysis.
Funnel plot with pseudo 95% confidence limits
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Figure 2. Funnel plot showing publication bias for the 58 included
studies providing HR and CI. Plotted points are frequently seen away
from the ‘0’.
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Table 2. Extracted data from biomarker articles
IHC
target N
Positive
cases
Primary
antibody
(dilution)
Reference
group
Uni or
Multivariate Survival HR CI P-value
Evasion of growth supressors
Evangelou et al, 2008 Caspase-3 35 NA Cell signalling
Bioline (1 : 100)
Labelling index Univariate DFS o0.01a 0.298–3.302a 0.990
Evangelou et al, 2008 E2f-1 35 23 (66%) Santa Cruz (1 : 100) 435% cells labelling index Univariate DFS 3.908 0.153–0.992a 0.048
Cavazzola et al, 2009 p53 38 24 (52%) Sigma Biosciences
(1 : 100)
410% Multivariate CSS 1.429 0.429–4.725 0.514
Moskaluk et al, 1996 p53 88 40 (45%) Novocastra (NA) 450% Univariate OS 1.46 0.87–2.46 0.155
Madani et al, 2010 p53 142 48 (34%) Dako (1 : 50) þ 2 to þ 8 Univariate OS 1.64 1.1–2.45 0.014
Sustained Proliferative signalling
Langer et al, 2006 EGFR 137 72 (53%) Cytomed (1 : 60) 410% cells þ ve. Univariate OS 0.99 0.98–1.00a 0.039
Ong et al, 2013 EGFR 359 36 (10%) Novocastra (1 : 10) þ 2, þ 3 Univariate OS 1.520 1.03–2.26 0.040
Ong et al, 2013b EGFR 663 NA Novocastra (1 : 10) þ 1 Univariate OS 0.83 0.66–1.04 .10
100 (15%) þ 2 1.41 .05–1.91 0.02
þ 3 0.94 0.58–1.52 0.80
Wang et al, 2007 EGFR 103 33 (32%) Dako (NA) 45% Univariate OS 1.93 1.24–3.02 0.004
Nakamura et al, 1994 HER2 62 15 (19%) Boehringer
Mannheim
Biochemica (NA)
þ 2 Univariate OS 4.100 1.4–11.8 0.015
Yoon et al, 2012 HER2 708 119 (17%) Herceptest (NA) þ 2, þ 3 Univariate OS 0.760 0.59–0.96 0.024
Phillips et al, 2013 HER2 135 31 (23%) Ventana (NA) þ 2, þ 3 Multivariate OS 0.840 0.53–1.33 0.470
Dutta et al, 2012 Ki67 98 NA Dako (1 : 50) Slidepath scoring
algorithm. Tertiles.
Univariate CSS 1.460 1.01–2.12 0.048
Evangelou et al, 2008 Ki67 35 NA Dako (1 : 100) o35% cells þ ve, labelling
index
Univariate DFS 3.757 0.986–11.68 0.050
Falkenback et al, 2008 Ki67 59 50 (85%) Dako (1 : 1000) 0–10% Univariate CSS 3.900 1.7–9.1 o0.001
Tuynman et al, 2008 MET 145 78 (54%) Zymed (1 : 100) þ 2, þ 3 Univariate DFS 2.300 1.3–4.1 0.004
Prins et al, 2013 p-mTOR 147 29 (19.7%) Cell Signalling
Technology (1 : 50)
2þ , 3þ Univariate CSS 1.648 1.019–2.664 0.042
Ong et al, 2013 PAPSS2 337 216 (64%) Abcam (1 : 600) þ 2, þ 3 Univariate OS 1.240 0.96–1.61 0.100
Schoppmann et al, 2012 pSTAT3 179 72 (40%) Cell Signalling
Technology
(1 : 100)
410 (4median) Univariate OS 1.982 1.186–3.311 0.050
Bettstetter et al, 2013 PTEN 117 101 (86%) Cell Signalling
Technology (1 : 50)
475% Multivariate OS 0.451 0.233–0.873 0.018
Escape from immune surveillance
Loos et al, 2011 B7-H1 101 74 (73%) Abcam (NA) 4þ4
(Intensityþproportion of
cells)
Univariate OS 2.92 1.50–5.66 o0.001
Rauser et al, 2010 CD3 99 57 (58%) NeoMarkers
(1 : 100)
42.0 Labelling indices Univariate OS 0.49 0.28–0.85 0.012
Zingg et al, 2010 CD3 central 105 NA Dako (1 : 50) 4563 (4median count) Univariate OS 0.53 0.33–0.84 0.008
Zingg et al, 2010 CD4 central 105 58 (55%) NeoMarkers (1 : 40) 430 (4median count) Univariate OS 0.74 0.47–1.16 0.187
Zingg et al, 2010 CD25 central 105 NA NeoMarkers (1 : 10) 433 (4median count) Univariate OS 0.76 0.48–1.22 0.262
Zingg et al, 2010 CD8 central 105 51 (49%) Dako (1 : 50) 4225 (4median count) Univariate OS 0.44 0.27–0.69 o0.001
Dutta et al, 2012 CD8 tertiles 98 NA Dako (1 : 100) Slidepath scoring algorithm Univariate CSS 0.69 0.48–0.99 0.048
Rauser et al, 2010 CD45RO 110 93 (85%) Dako (1 : 1200) 40.9 Labelling indices Univariate DFS 0.44 0.23–0.84 0.013
Dutta et al, 2012 CD68 98 NA Dako (1 : 200) Slidepath scoring
algorithm. Tertiles.
Univariate CSS 1.38 0.99–1.94 0.061
Zingg et al, 2010 FoxP3 central 105 46 (43%) eBioscience (1 : 50) 4117 (4median count) Univariate OS 0.65 0.40–1.05 0.079
Deregulation of cellular energetics
Birner et al, 2011 CAIX 182 85 (47%) Abcam (1 : 1000) 4median score (20 out of
score 0–300)
Univariate OS 1.844 1.11–3.08 0.007
Tumour promoting inflammation
Wang et al, 2006 ANXA1 104 41 (39%) BD Biosciences
(1 : 100)
425% Univariate OS 1.930 1.25–2.99 0.003
Bhandari et al, 2006 COX-2 90 NA Cayman Chemical
(1 : 100)
4200 Univariate CSS 3.530 2.11–5.89 o0.001
Buskens et al, 2002 COX-2 145 115 (79%) Cayman Chemical
(1 : 200)
þ 2, þ 3 Univariate OS 3.200 1.5–7.1 0.002
Prins et al, 2012 COX-2 147 39 (27%) Cayman Chemical
(1 : 100)
þ 3 Univariate OS 1.700 1.07–2.69 0.023
Tuynman et al, 2008 COX-2 145 78 (54%) Cayman Chemical
(1 : 200)
þ 2, þ 3 Univariate DFS 1.400 0.8–2.6 0.234
Evasion of apoptosis
Ong et al, 2013 DCK 355 126 (36%) Lifespan
Biosciences (1 : 10)
þ 2, þ 3 Univariate OS 0.980 0.75–1.28 0.860
Chandra et al, 2002 GSTp 15 6 (40%) Vector laboratories 3þ Univariate DFS 2.250 0.71–7.17 0.350
Ong et al, 2013 MTMR9 356 88 (25%) Novus (1 : 350) þ 2, þ 3 Univariate OS 1.140 0.87–1.51 0.340
Ong et al, 2013 NEIL2 357 198 (55%) Sigma-Aldrich
(1 : 50)
þ 2, þ 3 Univariate OS 1.120 0.87–1.43 0.390
Ong et al, 2013 SIRT2 359 156 (44%) Atlas Antibodies
(1 : 100)
þ 2, þ 3 Univariate OS 1.310 1.03–1.67 0.030
Ong et al, 2013b SIRT2 663 NA Atlas Antibodies
(1 : 100)
2 Univariate OS 1.69 1.10–2.60 0.02
290 (44) 1 1.81 1.24–2.64 o0.01
0 1.37 0.96–1.97 0.08
Ong et al, 2013 WT1 358 19 (5%) Dako (1 : 800) þ 2, þ 3 Univariate OS 0.710 0.39–1.30 0.270
BRITISH JOURNAL OF CANCER Prognostic biomarkers in oesophageal adenocarcinoma
110 www.bjcancer.com |DOI:10.1038/bjc.2015.179
CD8. CD8 is a marker of cytotoxic T cells. CD8þ cells kill cancer
cells via release of granzyme and perforin or via Fas ligand
presentation (Owen et al, 2013). This is an area of considerable
interest with trials in a number of solid organ cancers examining
strategies to enhance tumour-cell killing. The discovery of the role
of PD-L1 on tumour cells and its interaction with the PD-1
receptor on cyctotoxic T cells leading to immune cell exhaustion
have led to the development of antibodies targeting both the
Table 2. ( Continued )
IHC
target N
Positive
cases
Primary
antibody
(dilution)
Reference
group
Uni or
Multivariate Survival HR CI P-value
Inducing angiogenesis
Dutta et al, 2012 CD34 98 NA Dako (1 : 150) Slidepath scoring
algorithm. Tertiles.
Univariate CSS 0.94 0.67–1.34 0.736
Cavazzola et al, 2009 VEGF 38 22 (48%) Santa Cruz (1 : 400) 430% cells stained Multivariate CSS 0.369 0.095–1.436 0.115
Prins et al, 2012 VEGF 143 90 (63%) R&D systems
(1 : 50)
4þ1 Univariate CSS 1.900 1.22–2.96 0.005
Xie et al, 2013 VEGF-C 128 96 (75%) Santa Cruz (1 : 50) 40.18 Mean optical
density
Multivariate DFS 3.491 2.156–5.652 o0.0001
Tissue invasion and metastasis
Hector et al, 2010 AXL 92 56 (61%) R&D systems
(1 : 100)
þ 3 Multivariate OS 1.91 1.04–3.49 0.036
Falkenback et al, 2008 E-cadherin 59 44 (75%) Dako (1 : 100) Absent/reduced Univariate CSS 3.900 1.2–12.9 0.017
Becker et al, 2010 LgR5 24 NA MBL Internation
Co (1 : 50)
45 (Intensityþproportion) Univariate OS 2.860 1.08–7.61 0.040
von Rahden et al, 2011 LgR5 60 51 (85%) Abcam (NA) 415% Univariate OS 2.418 1.17–4.99 0.033
Grimm et al, 2010 MMP-1 60 33 (55%) Hiddenhausen
(NA)
446% Univariate OS 1.453 0.7101–2.9718 0.307
Streppel et al, 2012 Mucin 16 95 66 (70%) Abcam (1 : 200) Moderate/Diffuse Univariate NA 1.410 0.734–2.709 0.303
Wijnhoven et al, 2005 p120 96 65 (67%) Transduction
laboratories
(1 : 1000)
o90% Multiivariate OS 2.100 1.1–4.2 0.006
Schoppmann et al,
2013b
Podoplanin
(lymphovascular
invasion)
194 81 (42%) Ventana (NA) Tumour cluster in
podoplanin decorated
space
Univariate OS 1.863 1.086–0.195a o0.01
Schoppmann et al,
2013a
Podoplanin
(CAFs)
200 118 (59%) Venatana (1 : 300) 410% CAFs Univariate OS 1.843 1.097–3.096 0.001
Birner et al, 2012 RKIP 179 NA Upstage/Millipore
(1 : 1000)
480 out of score 0–300
(4median score)
Multivariate DFS 0.494 0.278–0.878 0.016
Ong et al, 2013 TRIMM44 349 197 (56%) Protein Tech group
(1 : 50)
þ 2, þ 3 Univariate OS 1.310 1.01–1.70 0.040
Ong et al, 2013b TRIMM44 655 NA Protein Tech group
(1 : 50)
þ 1 Univariate OS 1.46 0.89–2.44 0.4
442 (67%) þ 2 1.59 0.96–2.63 0.07
þ 3 1.94 1.09–3.44 0.02
Laerum et al, 2012 uPAR (Cancer
cells)
60 37 (62%) Raised in-house þ 2, þ 3, þ 4 Univariate OS 2.020 1.11–3.66 0.021
Laerum et al, 2012 uPAR
(Macrophages)
60 57 (95%) Raised in-house þ 2, þ 3, þ 4 Univariate OS 1.120 0.62–2.01 0.710
Laerum et al, 2012 uPAR
(myofibroblasts)
60 39 (65%) Raised in-house þ 2, þ 3, þ 4 Univariate OS 1.600 0.86–2.99 0.140
Abbreviations: CI¼ confidence interval; CSS¼ cancer-specific survival; DFS¼disease-free survival; IHC¼ immunohistochemical; HR¼hazard ratio; OS¼overall survival.
aValues as documented in original articles. Incorrect values excluded from meta-analysis.
bValidation cohorts from same study not used in meta-analysis due to differences in cut-offs.
Angiogenesis
(VEGF)
Tumour
promoting
inflammation
(ANXA1, COX-2)
Tissue invasion
and metastasis
(AXL, E-cadherin, LgR5,P120,
CAFs, TRIM44,RKIP)
Sustained proliferative signalling
(EGFR, Ki67, HER2, MET, p-m TOR, pSTAT3, PTEN)
Evasion of growth suppressors
(p53, E2f-1)
Deregulation of
cellular energetics
(CAIX)
Evasion of
apoptosis
(SIRT2)
Escape from immune
surveillance
(CD3, CD8, CD45R0, B7-H1)
Figure 3. Statistically significant prognostic biomarkers from at least one study in resected oesophageal adenocarcinoma covering all hallmarks
of cancer.
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receptor and its ligand (McDermott and Atkins, 2013). Two studies
were pooled examining CD8 (cytotoxic, T-cell effector), compris-
ing a total of 203 cases (Zingg et al, 2010; Dutta et al, 2012).
Moderate heterogeneity is observed (I2¼ 54.5%). Methodological
differences may be the cause of the heterogeneity, with observation
of increasing CD8þ count across three tertiles, vs CD8 with a
cutoff set for high vs low expression (Zingg et al, 2010; Dutta
et al, 2012).
EGFR. EGFR is a receptor tyrosine kinase, shown to have effects
on cancer differentiation, proliferation, invasion and metastasis
(Grandis and Sok, 2004). EGFR targeting is used in the treatment
COX2:
Study
Study
Study
Study
Study
Study
Study
Study
Study
Buskens CJ, 2002
Prins MJ, 2012
Bhandari P, 2006
Overall: HR 2.47(1.15–3.79)
Overall: HR 0.51 (0.32–0.70)
Overall: HR 0.55 (0.31–0.80)
Overall: HR 1.65 (1.14–2.16)
Overall: HR 1.56 (1.06–2.06)
Overall: HR 0.77 (0.61–0.94)
Overall: HR 2.53 (0.88–4.18)
Overall: HR 1.81 (0.59–3.03)
Overall: HR 0.69 (0.21–1.17)
Hazard ratio
Hazard ratio
Hazard ratio
Hazard ratio
Hazard ratio
Hazard ratio
Hazard ratio
Hazard ratio
Hazard ratio
3.20
0.53
0.44
1.52
1.46
0.76
2.42
3.90
0.88
0.37
1.46
3.76
2.86
0.84
1.43
1.64
1.93
0.69
0.49
1.70
3.53
95% confidence interval
95% confidence interval
95% confidence interval
95% confidence interval
95% confidence interval
95% confidence interval
95% confidence interval
95% confidence interval
95% confidence interval
1.50–7.10
1.07–2.69
0.33–0.84
0.27–0.69
1.03–2.26
0.87–2.46
0.59–0.96
1.17–4.99
1.70–9.10
0.09–1.44
0.54–1.42
1.01–2.12
0.99–11.68
1.08–7.61
0.53–1.33
0.43–4.72
1.10–2.45
1.24–3.03
0.48–0.99
0.28–0.85
2.11–5.89
Tests of heterogeneity: I2= 46.2%
Tests of heterogeneity: I2= 0.0%
Tests of heterogeneity: I2= 54.5%
Tests of heterogeneity: I2= 0.0%
Tests of heterogeneity: I2= 0.0%
Tests of heterogeneity: I2= 0.0%
Tests of heterogeneity: I2= 0.0%
Tests of heterogeneity: I2= 13.2%
Tests of heterogeneity: I2= 35.9%
Weight (%)
Weight (%)
Weight (%)
Weight (%)
Weight (%)
Weight (%)
Weight (%)
Weight (%)
Weight (%)
16.79
54.67
55.54
54.36
67.93
39.61
82.38
74.50
85.21
37.24
62.76
4.96
9.84
25.50
17.62
5.44
54.95
32.07
45.64
44.46
28.54
P=0.156
P=0.838
P=0.138
P=0.459
P=0.938
P=0.722
P=0.819
P=0.316
P=0.212
CD3:
CD8:
Zingg U, 2010
Zingg U, 2010
Rauser S, 2010
Dutta S, 2012
EGFR:
p53:
HER2:
LgR5:
Ki67:
VEGF:
Ong CA, 2013
Wang K, 2007
Moskaluk CA, 1996
Cavazzola LT, 2009
Madani K, 2010
Yoon HH, 2012
Phillips BE, 2013
Von Rahden BH, 2011
Becker L, 2010
Falkenback D, 2008
Dutta S, 2012
Evangelou K,2007
Cavazzola LT, 2009
Prins MJ, 2012
Figure 4. Forest plots with associated hazard ratio (HR) and 95% confidence interval. Weights calculated using a random effects model.
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of colorectal cancer and non-small cell lung cancer (Mahipal et al,
2014). A total of 642 patients were pooled from two studies (Wang
et al, 2007; Ong et al, 2013). Combined, an overall, slight-negative,
prognostic effect of EGFR overexpression was found. This is in
agreement with other studies in OAC that were unsuitable for
meta-analysis (Mukaida et al, 1991; Yacoub et al, 1997; Lennerz
et al, 2011). This effect on prognosis with overexpressed EGFR has
been noted in both colorectal cancer and gastric adenocarcinoma
(Rego et al, 2010; Hong et al, 2013).
p53. p53 acts as a hub for multiple intra-cellular surveillance
systems, constantly reporting on cellular integrity. When stress is
detected, a damaged cell can initiate DNA repair, senescence and/
or apoptosis. TP53 mutation can increase protein stability,
meaning IHC detection correlates with mutation (Bellini et al,
2012). However IHC does not account for all mutations, with
between 52% and 80% agreement between IHC and PCR with
truncating and missense mutations (Bian et al, 2001). TP53 is the
most commonly mutated gene in OAC and has recently been
found to have a mutational frequency that would distinguish
between disease stages and thus identify progression towards
malignancy (Weaver et al, 2014).
Eleven studies examining p53 were reviewed in full (Flejou et al,
1994; Casson et al, 1995; Sauter et al, 1995; Moskaluk et al, 1996;
Hardwick et al, 1997; Casson et al, 1998, 2003; Jiao et al, 2003;
Heeren et al, 2004; Cavazzola et al, 2009; Madani et al, 2010). Only
three of these were suitable for inclusion in the systematic review
and subsequent meta-analysis, containing a total of 268 patients
and showing a pooled effect of worse prognosis with increased
expression (Moskaluk et al, 1996; Cavazzola et al, 2009; Madani
et al, 2010). Good agreement is seen between the three included
studies. However, five other studies not included in the review
failed to reach significance, suggesting that the prognostic value of
p53 may not be as obvious as the meta-analysed results suggest
(Duhaylongsod et al, 1995; Coggi et al, 1997; Hardwick et al, 1997;
Langer et al, 2006; Falkenback et al, 2008).
HER2. HER2 exhibits extensive homology with EGFR, frequently
dimerising with it or another member of the EGFR family HER3
(Wolf-Yadlin et al, 2006). HER2 is overexpressed in a number of
cancers and undergoes a ligand-independent activation, with
consequent downstream signals involved in proliferation and
migration (Wolf-Yadlin et al, 2006). HER2 provides a target for the
monoclonal antibody trastuzumab, which has proven efficacy in
breast and gastric cancer treatment (Hynes and Lane, 2005; Bang
et al, 2010). HER2 targeting in OAC is being assessed in the
feasibility arm of the MRC STO3 clinical trial (Okines et al, 2013).
Two studies were suitable for pooling, showing an OS benefit
with overexpression of HER2 (Nakamura et al, 1994; Yoon et al,
2012; Phillips et al, 2013). Both studies used the ToGA trial
protocol to assess HER2 overexpression, including FISH analysis of
ErbB2 gene amplification. This effect has failed to be reproduced
by smaller studies, potentially as a result of under powering
(Polkowski et al, 1999; Reichelt et al, 2007; Hu et al, 2011;
Thompson et al, 2011). The overall protective effect seen here is in
contrast to studies investigating OAC using techniques other than
IHC, where a negative prognostic effect is noted, as well as in
breast cancer, where a dramatically worse prognosis is seen with
overexpression (Andrulis et al, 1998; Chan et al, 2012).
LgR5. The R-spondin receptor Lgr5 is a stem cell marker in
multiple organs in mice and humans. Single Lgr5 stem cells derived
from the intestine can be cultured to build epithelial structures that
retain hallmarks of the in vivo epithelium (Sato and Clevers, 2013).
In tumours, Lgr5 expression is believed to define cancer stem cells
and may have prognostic effects by promoting invasion and
metastasis as well as initiating self-renewal pathways (Reya and
Clevers, 2005). Despite the vast majority of cancer deaths
being attributable to invasion and metastasis, Lgr5 was the
only suitable biomarker for meta-analysis with its main function
associated with this hallmark of cancer (Becker et al, 2010; von
Rahden et al, 2011).
Lgr5 failed to reach statistical significance as a prognostic
marker. This was due to the wide, asymmetric CIs, resulting from
under powering with only 84 cases in total across the two studies
(Becker et al, 2010; von Rahden et al, 2011).
VEGF. VEGF is upregulated in response to hypoxia, acting as a
key mediator of angiogenesis and affecting vessel permeability,
potentially enhancing haematogenous dissemination (Hicklin and
Ellis, 2005). Two studies contributed to VEGF meta-analysis, with
a total of 181 patients, producing a non-significant effect on
survival (Cavazzola et al, 2009; Prins et al, 2012). Again, few
studies have examined prognosis and angiogenesis, with contra-
dictory results seen in small cohorts (Couvelard et al, 2000; Saad
et al, 2005). With emerging targeted therapies, further work will be
required to confirm whether VEGF is a true driver of cancer
aggressiveness (Shah et al, 2011).
Ki67. Despite the common use of Ki67 to index cellular
proliferation, its biological function in the tumour remains elusive.
It seems to co-localise with ribosomal RNA during mitosis
suggesting a role in protein synthesis and, more recently,
chromatin remodelling (Bullwinkel et al, 2006).
Here, three studies were pooled, comprising a total of 192
patients (Evangelou et al, 2008; Falkenback et al, 2008; Dutta et al,
2012). A non-significant result was observed. Again, this could be
due to a combination of asymmetrical wide CIs in two studies,
combined with marginal prognostic value in the other. In breast
cancer, increased cellular proliferation index has been studied as a
negative prognostic marker and in directing use of chemotherapy
against rapidly dividing tumours (Martin et al, 2004; de Azambuja
et al, 2007; Yerushalmi et al, 2010). However, Ki67 expression
is understudied in OAC, and prognostic significance remains
inconclusive.
Publication bias. Within the 214 relevant articles, 92 of these
provided HRs and statistical significance, 52 (57%) of these
provided non-significant results. This is in contrast to the final
36 articles that met REMARK inclusion criteria, where only six
(18%) centred on non-significant results. Asymmetry was noted
when all data was viewed on a funnel plot (Figure 2) suggesting
positive publication bias.
DISCUSSION
Previous meta-analysis of oesophageal cancer examining individual
molecules of prognosis have combined OAC and SCC in addition
to using different investigational techniques for analysis
(Vallbohmer and Lenz, 2006; Ong et al, 2010; Chan et al, 2012;
Chen et al, 2012, 2013; Peng et al, 2013; Gowryshankar et al, 2014).
There is consensus that OAC and SCC should be considered as
separate biological entities and current clinical trials in oesophageal
cancer reflect this approach. To date, this is the first meta-analysis
that has synthesised the literature associated with all IHC markers
solely in resected OAC. Using a validated prognostic marker-
reporting tool to inform our strict inclusion and exclusion criteria,
we identified 36 high-quality articles providing reliable HRs and
CIs (McShane et al, 2005). From these articles, nine markers were
suitable for meta-analysis and of these six markers showed
significant correlation with survival. These markers were COX-2,
CD3, CD8, HER2, EGFR and p53. Several other molecules have
been assessed in good quality studies that met the REMARK
inclusion criteria, but do not have a second study available for
pooling. Of particular interest, MET, B7-H1, CAIX, ANXA1 and
Prognostic biomarkers in oesophageal adenocarcinoma BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.179 113
VEGF-C all showed significant, highly prognostic effects in cohorts
containing over 100 cases but still require validation and/or
elucidation of the underlying biology.
A number of the molecules identified in this review are
related to emerging therapies. Four of the nine meta-analysed
markers (COX-2 – celecoxib, EGFR – gefitinib, HER2 –
trastuzumab and VEGF – bevacizumab) focussed on molecules
with targeted therapeutics either already in use or in develop-
ment, and two lymphocyte markers representing the presence
of effectors of anti-tumour immunity, which can be induced by
new therapies (Zhang et al, 2003; Galon et al, 2006; Ekman et al,
2008; Mei et al, 2014; Ward et al, 2014). As well as new therapies,
there is an increasing interest in the role the cancer micro-
environment has in OAC progression (Courrech Staal et al,
2011). Here, CD3 and CD8 demonstrate the greatest protective
prognostic impact, illustrating the importance of the immune
response to OAC. However, IHC analysis of other components
of the microenvironment have been largely neglected, for
example, only two papers comment on the impact of cancer-
associated fibroblasts on prognosis (Laerum et al, 2012;
Schoppmann et al, 2013a).
The most striking observation of this meta-analysis is the
scarcity of high-quality articles, with 66% (69 out of 104) of
potentially suitable studies not conforming to REMARK criteria.
In similar meta-analyses published on the two cancers with
worse prognoses than OAC, 83 suitable articles were pooled for
pancreatic cancer prognosis, and in lung cancer, enough data were
found to analyse 17 markers studied in four or more papers (Zhu
et al, 2006; Jamieson et al, 2011; Peng et al, 2013). This suggests
that prognostic marker research in OAC is lacking. In addition,
despite the majority of patients now receiving some form of
neoadjuvant therapy before resection for OAC (Noble et al, 2013),
we found this to be poorly reported in these studies. It was
therefore impossible to make any attempt to discriminate
between markers prognostic after primary resection or after
neoadjuvant therapy. Future reports should include a detailed
description of the types of multimodal treatment given to
patients and preferably include an analysis based on these
treatment types.
A trend was noticed towards more robust methodology when
authors used larger data sets. The largest study identified used
independent generation and validation data sets to confirm the
prognostic significance of the novel markers SIRT2 and TRIMM44.
The analysis was performed in two different patient cohorts from
separate centres and was of high quality (Ong et al, 2013).
However, we were unable to include this study in the meta-analysis
because the cutoffs used to assess the HRs in the two cohorts were
different. SIRT2 and TRIMM44 require validation using the same
methodology and cutoffs in another cohort. Despite this, the study
by Ong et al (2013) describes a sophisticated approach to the
development of a biomarker based on genetic analysis carried
through to the protein level. Genome sequencing studies such as
the UK ICGC project in OAC (Weaver et al, 2014) will deliver
more potential markers of prognosis in selected sub-groups and
methods such as those described by Ong et al (2013) will be
required to translate these findings into meaningful clinical
outcomes.
Authors who appeared more than once in the 214 initial articles,
often adhered to REMARK criteria, and provided log-rank or cox
regression hazard calculations. This suggests a gradual uptake of
REMARK criteria, since it’s inception in 2005. Another potential
reason for this poorer reporting in smaller studies may be due to
more frequent negative results due to inadequate powering. With
an overall reluctance towards negative reporting, it is quite possible
that these results are left out as redundant data, with the larger data
sets having more positive results, and a greater likelihood of
publication.(Kyzas et al, 2007)
Limitations. Meta-analysis is able to enhance power that leads to
more robust generalisations within a field. However, there are
notorious confounding factors (Altman, 2001).
Here, only one study was prospective in design (Madani et al,
2010). Retrospective analysis allows potential issues in reporting
and selection bias. With differences in multivariate or univariate
analysis, CSS or OS, size of cohorts, cutoffs, primary antibody at
different dilutions and occasionally radically different numbers of
positive staining cases lead to less validity when combining results.
Future work will require multi-centre efforts to gather large
enough, prospective cohorts to provide robust clarification of truly
prognostic markers.
With this meta-analysis we have only included IHC detectable
markers of survival. Both IHC and RT-PCR have their own
limitations; however, IHC is seen to be the most practical way to
assess protein expression in solid cancers, with IHC survival
biomarkers well described in other malignancies (Zhu et al, 2006;
Jamieson et al, 2011).
In future work, multivariate modelling will give an insight into
interaction between different variables in OAC. In this study,
univariate analysis was used preferentially, to limit heterogeneity
between methods of producing HRs, as a multivariate HR can be
altered by use of different prognostic factors or model types in
individual models. In fact, it is likely that a combination of markers
will be required to give meaningful prognostic information to an
individual patient, perhaps covering multiple Hallmarks of Cancer,
rather than considering individual biomarkers in isolation. There
are existing data from oesophageal cancer biology to support this
strategy (Kadri et al, 2010; Peters et al, 2010; Liu et al, 2014).
CONCLUSION
Current methods have not delivered clinically useful molecular
prognostic biomarkers in OAC. We have highlighted the paucity
of good-quality robust studies in this field. This may be because
little attention has been focused on OAC research compared with
other cancers, or perhaps it is an indication of the molecular
complexity of the disease that is only just beginning to be
appreciated. The development of new and novel biomarkers in
OAC will require understanding of this complexity and in this
context IHC alone seems inappropriate. A genome to protein
approach would be better suited for the development and
subsequent validation of biomarkers. Large collaborative projects
with standardised methodology will be required to generate
clinically useful biomarkers.
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